Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

44.95
+1.152.63%
Post-market: 44.88-0.0700-0.16%17:50 EST
Volume:318.25K
Turnover:14.27M
Market Cap:1.24B
PE:-15.63
High:45.39
Open:43.71
Low:43.60
Close:43.80
52wk High:46.56
52wk Low:12.21
Shares:27.69M
Float Shares:14.25M
Volume Ratio:0.73
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8757
EPS(LYR):-5.1170
ROE:-308.02%
ROA:-4.23%
PB:-42.31
PE(LYR):-8.78

Loading ...

GSK: Breach Entitles to Reduce Royalties and Milestone Payments Due by Tesaro to AnaptysBio by 50%

THOMSON REUTERS
·
Nov 21

GSK: Recent Conduct by AnaptysBio Is in Material Breach of Existing License Agreement With Tesaro Regarding Oncology Treatment Jemperli

THOMSON REUTERS
·
Nov 21

GSK-Started Litigation After AnaptysBio's Allegations That Tesaro Has Not Fulfilled Certain Requirements of License Agreement Entered in March 2014

THOMSON REUTERS
·
Nov 21

GSK: GSK and Tesaro Are Firmly of View That These Allegations Are Entirely "Without Merit"

THOMSON REUTERS
·
Nov 21

AnaptysBio (ANAB): Evaluating Valuation After Phase 2 Ulcerative Colitis Trial Discontinuation and Cost Savings

Simply Wall St.
·
Nov 20

U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare

Reuters
·
Nov 13

AnaptysBio Inc : JP Morgan Cuts Target Price to $67 From $79

THOMSON REUTERS
·
Nov 13

Stock Track | AnaptysBio Plummets 5.24% as Analysts Slash Price Targets Following Phase 2 Trial Results

Stock Track
·
Nov 11

AnaptysBio : Barclays Cuts Target Price to $70 From $83

THOMSON REUTERS
·
Nov 11

TD Cowen Reaffirms Their Buy Rating on AnaptysBio (ANAB)

TIPRANKS
·
Nov 11

Barclays Keeps Their Buy Rating on AnaptysBio (ANAB)

TIPRANKS
·
Nov 11

AnaptysBio Down Over 14%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

Dow Jones
·
Nov 11

AnaptysBio price target lowered to $50 from $70 at Wedbush

TIPRANKS
·
Nov 11

AnaptysBio Is Maintained at Hold by Truist Securities

Dow Jones
·
Nov 11

Wedbush Adjusts Price Target on AnaptysBio to $50 From $70, Maintains Outperform Rating

MT Newswires Live
·
Nov 11

BUZZ-AnaptysBio falls after ulcerative colitis drug fails in mid-stage trial

Reuters
·
Nov 10

AnaptysBio Inc : Leerink Partners Cuts Target Price to $58 From $62

THOMSON REUTERS
·
Nov 10

Stock Track | AnaptysBio Plummets 19% as Rosnilimab Fails to Meet Ulcerative Colitis Trial Endpoints

Stock Track
·
Nov 10

AnaptysBio price target raised to $36 from $20 at Truist

TIPRANKS
·
Nov 10

AnaptysBio Halts Rosnilimab Ulcerative Colitis Trial After Missing Phase 2 Endpoints

Reuters
·
Nov 10